PANAMA CITY, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Copa Holdings, S.A. (NYSE: CPA) today released preliminary passenger traffic statistics for January 2025:

SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT.

Jerash Holdings (US), Inc. (NASDAQ:JRSH ) Q3 2025 Earnings Conference Call February 11, 2025 9:00 AM ET Company Participants Roger Pondel - IR, PondelWilkinson Sam Choi - Chairman & CEO Eric Tang - Executive Director Gilbert Lee - CFO Conference Call Participants Mark Argento - Lake Street Michael Baker - D.A. Davidson Igor Novgorodtsev - Lares Capital Operator Good morning.

WK Kellogg Co (NYSE:KLG ) Q4 2024 Earnings Conference Call February 11, 2025 9:30 AM ET Company Participants Karen Duke - VP of Finance & IR Gary Pilnick - Chairman and CEO Dave McKinstray - CFO Conference Call Participants Andrew Lazar - Barclays Peter Galbo - Bank of America Kenneth Goldman - JPMorgan Max Gumport - BNP Paribas Matthew Smith - Stifel David Palmer - Evercore ISI Robert Dickerson - Jefferies Robert Moskow - TD Securities Operator Hello, everyone, and welcome to the WK Kellogg Fourth Quarter 2024 Earnings Call. My name is Lydia, and I'll be your operator today.

TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) (the “Company”) is pleased to announce it has closed its previously announced offering of 5.25% convertible senior notes due 2030 (the “Notes”) in an aggregate principal amount of $110 million (the “Offering”), which includes the upsized offering of $95 million and the exercise in full of the $15 million option granted to the initial purchasers of the Notes. All amounts are in United States Dollars.

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9 https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86b https://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9 https://www.globenewswire.com/NewsRoom/AttachmentNg/072d748b-3237-48ad-8d83-1c6c23dda65f STAMFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that …

Vornado Realty Trust (NYSE:VNO ) Q4 2024 Earnings Conference Call February 11, 2025 10:00 AM ET Company Participants Steven Borenstein - Senior Vice President & Corporate Counsel Steven Roth - Chairman & Chief Executive Officer Michael Franco - President & Chief Financial Officer Glen Weiss - Executive Vice President, Office Leasing & Co-Head, Real Estate Conference Call Participants Steve Sakwa - Evercore ISI John Kim - BMO Capital Markets Jeff Spector - Bank of America Dylan Burzinski - Green Street Capital Floris van Dijkum - Compass Point Michael Griffin - Citi Vikram Malhotra - Mizuho Securities Michael Lewis - Truist …

Streaming giant Netflix Inc NFLX has opened a new restaurant experience in Las Vegas as part of its continuing efforts to diversify its revenue thanks to loyal fan bases.

AI-driven energy demands have boosted utility stocks, but DeepSeek's efficient AI approach questions future growth projections, impacting the Virtus Reaves Utilities ETF (UTES). UTES saw significant gains in 2024, led by top holdings like Constellation Energy and Vistra, but current high valuations may not be sustainable if projections change. Environmental and regulatory challenges complicate utility expansions, making it difficult for UTES to find alternative growth opportunities within its top holdings.

Facing a drop in US market share, WK Kellogg (KLG) hopes to glaze over the issue.

Major U.S. equities indexes were mixed and little changed as Federal Reserve Chair Jerome Powell began his two-day stint of testimony before Congress, stressing that the central bank will maintain a cautious approach.

Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other markets, Axsome's pipeline, including AXS-07 and AXS-12, shows potential for substantial revenue growth.

NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SAN JOSE, Calif.--(BUSINESS WIRE)--Momentus Inc. (NASDAQ: MNTS) (“Momentus” or the “Company”), a U.S. commercial space company that offers satellite buses, transportation, and other in-space infrastructure services, today announced the closing of its previously announced “reasonable best efforts” offering with a single institutional investor for the purchase and sale of 1,273,886 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 1,273,886 shares.

Brixmor Property Group Inc. (NYSE:BRX ) Q4 2024 Earnings Conference Call February 11, 2025 10:00 AM ET Company Participants Stacy Slater - SVP, IR Jim Taylor - CEO Brian Finnegan - President and COO Steve Gallagher - EVP and CFO Conference Call Participants Samir Khanal - Evercore ISI Andrew Reale - Bank of America Greg McGinniss - Scotiabank Craig Mailman - Citi Dori Kesten - Wells Fargo Juan Sanabria - BMO Capital Markets Connor Mitchell - Piper Sandler Caitlin Burrows - Goldman Sachs Linda Tsai - Jefferies Paulina Rojas - Green Street Kenneth Billingsley - Compass Point Omotayo Okusanya - …

Exelixis (EXEL -2.06%), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and earnings. Announced on Feb. 11, 2025, the earnings release showcased Exelixis's performance amidst a challenging oncology landscape, with revenues surpassing year-over-year figures by 18.2%.

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the ordinary shares of ICON plc (“ICON” or the “Company”) (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, inclusive. For more information, submit a form at ICON plc Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at [email protected], or call us at (212) 951-2030.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Electronic Arts Inc. (NASDAQ:EA) resulting from allegations that EA may have issued materially misleading business information to the investing public. SO WHAT: If you purchased EA securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Rosen Law Firm PA WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ:TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public. SO WHAT: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

HOUSTON , Feb. 11, 2025 /PRNewswire/ -- Chord Energy Corp. (Nasdaq: CHRD) ("Chord" or the "Company") plans to announce its fourth quarter and year end 2024 financial and operating results on Tuesday, February 25, 2025 after market close. The Company will host a live webcast and conference call on Wednesday, February 26, 2025 at 10:00 a.m.